NasdaqGS - Delayed Quote USD
argenx SE (ARGX)
At close: 4:00 PM EST
After hours: 4:08 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,858,657.00
1,226,316.00
410,747.00
497,277.00
41,243.00
Cost of Revenue
194,110.00
117,835.00
29,431.00
--
--
Gross Profit
1,664,547.00
1,108,481.00
381,316.00
497,277.00
41,243.00
Operating Expense
1,920,784.00
1,529,119.00
1,105,234.00
857,176.00
521,811.00
Operating Income
-256,237.00
-420,638.00
-723,918.00
-359,899.00
-480,568.00
Net Non Operating Interest Income Expense
142,260.00
92,058.00
22,548.00
2,393.00
4,718.00
Other Income Expense
51,470.00
24,084.00
-27,942.00
-42,239.00
-129,502.00
Pretax Income
-62,507.00
-304,496.00
-729,314.00
-399,743.00
-605,352.00
Tax Provision
-22,214.00
-9,443.00
-19,720.00
8,522.00
3,103.00
Net Income Common Stockholders
-40,293.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Diluted NI Available to Com Stockholders
-40,293.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Basic EPS
-0.70
-5.16
-13.05
-7.99
-13.40
Diluted EPS
-0.78
-5.16
-13.05
-7.99
-13.40
Basic Average Shares
59,509.95
57,169.25
54,381.37
51,075.83
45,410.44
Diluted Average Shares
63,311.71
57,169.25
54,381.37
51,075.83
45,410.44
Total Operating Income as Reported
-263,319.00
-425,049.00
-720,341.00
-348,746.00
-477,617.00
Total Expenses
2,114,894.00
1,646,954.00
1,134,665.00
857,176.00
521,811.00
Net Income from Continuing & Discontinued Operation
-40,293.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Normalized Income
-78,036.54
-322,664.32
-683,066.22
-377,430.53
-513,918.54
Interest Income
144,298.00
92,962.00
24,741.00
3,489.00
5,119.00
Interest Expense
2,038.00
904.00
2,193.00
1,096.00
401.00
Net Interest Income
142,260.00
92,058.00
22,548.00
2,393.00
4,718.00
EBIT
-60,469.00
-303,592.00
-727,121.00
-398,647.00
-604,951.00
EBITDA
-60,469.00
-192,285.00
-622,779.00
-392,780.00
-601,034.00
Reconciled Cost of Revenue
194,110.00
8,894.00
29,431.00
--
--
Reconciled Depreciation
--
111,307.00
104,342.00
5,867.00
3,917.00
Net Income from Continuing Operation Net Minority Interest
-40,293.00
-295,053.00
-709,594.00
-408,265.00
-608,455.00
Total Unusual Items Excluding Goodwill
58,552.00
28,495.00
-27,265.00
-42,239.00
-129,502.00
Total Unusual Items
58,552.00
28,495.00
-27,265.00
-42,239.00
-129,502.00
Normalized EBITDA
-119,021.00
-220,780.00
-595,514.00
-350,541.00
-471,532.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
20,808.46
883.68
-737.22
-11,404.53
-34,965.54
12/31/2020 - 5/18/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALNY Alnylam Pharmaceuticals, Inc.
244.89
-0.77%
ASND Ascendis Pharma A/S
129.81
+5.85%
PCVX Vaxcyte, Inc.
88.54
+0.17%
BGNE BeiGene, Ltd.
190.51
-2.08%
IMVT Immunovant, Inc.
26.87
+1.24%
NAMS NewAmsterdam Pharma Company N.V.
20.20
+0.40%
MDGL Madrigal Pharmaceuticals, Inc.
347.45
+5.53%
CYTK Cytokinetics, Incorporated
49.10
+3.00%
BPMC Blueprint Medicines Corporation
94.15
-2.56%
PTGX Protagonist Therapeutics, Inc.
46.46
+11.55%